期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

EP4受体拮抗剂对雄激素非依赖性前列腺癌PC3细胞恶性表型的影响 被引量：1

Effect of EP4 receptor antagonist on malignant phenotypes of androgen-independent prostate cancer cells PC3
原文传递
导出
摘要 目的探讨EP4受体拮抗剂ONO-AE3-208对雄激素非依赖性前列腺癌(AIPC)PC3细胞的体外抗肿瘤效应。方法采用RT-PCR检测EP4受体mRNA在PC3细胞中的表达水平,实验组以0.1、1和10μmol/L的ONO-AE3-208作用于PC3细胞,对照组加入同体积的超轻水(ODW),采用MTT比色法、划痕愈合实验和细胞侵袭实验观察ONO-AE3-208对前列腺癌PC3细胞增殖、迁移和侵袭能力的抑制效应。结果 EP4受体在PC3细胞中呈高水平表达;随ONO-AE3-208作用时间和浓度的增加,其对PC3细胞的抑制率没有变化。PC3细胞的实验组细胞迁移比例为(25.30±6.11)%,低于对照组的(40.18±7.25)%(P<0.05)。实验组用0.1、1和10μmol/L的ONO-AE3-208作用于PC3细胞24h后,其穿入下室细胞数分别为(19.72±3.39)、(15.61±3.11)和(10.39±2.15)个/视野,少于对照组的(24.67±3.75)个/视野(P<0.05)。结论 EP4受体在AIPC PC3细胞中表达明显升高。EP4受体拮抗剂ONO-AE3-208对AIPC PC3细胞的增殖没有影响,但对其迁移和侵袭能力有明显的抑制作用。 Objective To investigate the anti-tumor effect of EP4 receptor antagonist ONO- AE3-208 on androgen-independent prostate cancer（AIPC） cells PC3 in vitro. Methods Quantative RT-PCR was used to examine the EP4 mRNA expression in the PC3 cells. The influenee of ONO- AE3-208 on the proliferation of the cells was observed by MTT assay. Wound-healing assay and Transwell invasion assay were used to evaluate the inhibitory effect of ONO-AE3-208 on the ability of migration and invasion- Results EP4 was highly expressed in cell lines PC3. As the time and concentration inereased,EP4 antagonist ONO-AE3-208 did not influence the proliferation of the cells （P〉0. 05）. The migration distance ratio of ONO-AF.3-208 10 μmol/L in treatment group was （25. 30±6. ll）%,which was lower than （40. 18±7.25）% in control group（P〈0. 05）. After treated with ONO-AE3-208 0. 1,1.0 and10 μmol/L for 24 hours,the numbers of PC3 cells were （19.72±3. 39）, （15.61±3. 11） and （10.39±2.15） pieces/view,which were more than （24. 67±3.75） pieces/view in control group（P〈0. 05）. Conclusion AIPC PC3 cells highly express EP4. EP4 antagonist ONO-AE3- 208 does not effect the proliferation of AIPC PC3, but can suppress its ability of migration and invasion.
作者 许松 王立明 葛京平 周文泉 张征宇
机构地区 第二军医大学南京临床学院 南京军区南京总医院泌尿外科 第二军医大学附属长征医院器官移植中心
出处 《江苏医药》 CAS 北大核心 2014年第5期497-500,F0002,共5页 Jiangsu Medical Journal
基金 国家自然科学基金(81372742)
关键词 EP4受体 前列腺癌 EP4 receptor Prostate cancer
分类号 R737 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Smith MR, Manola J, Kaufman DS, et al. Celecoxib versus placebo for men with prostate cancer and a rising serttrn prostate-specific antigen after radical prostatectomy and/or radiation therapy[J-]. J Clin Oncol, 2006,24 (18) : 2723-2728.
  • 2Terada N, Shimizu Y,Kamba T, et al. Identification of EP4 asa potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model EJ. Cancer Res, 2010,70(4) : 1606-1615.
  • 3Gupta S, Srivastava M, Abroad N, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma [-J "]. Prostate, 2000,42 (1) : 73-78.
  • 4Chen Y, Hughes-Fulford M. Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-los in human prostate cancer cellsEJ. Br J Cancer, 2000, 82(12) .. 2000-2006.
  • 5许松,周文泉,张征宇,葛京平,高建平.选择性环氧化酶2抑制剂塞来昔布对人前列腺癌PC-3细胞增殖与凋亡的影响[J].中华男科学杂志,2008,14(6):489-493. 被引量：7
  • 6Kuo KT, Wang HW, Chou TY, et al. Prognostic role of PGE2 receptor EP2 in esophageal squamous cell carcinoma [J]. Ann Surg Oneol, 2009,16(2) : 352-360.
  • 7Rohertson FM, Simeone AM, Lucei A, et al. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4 [J]. Cancer,2010,116(11 Suppl) :2806-2814.
  • 8Risbridger GP,Davis ID, Birrell SN,et al. Breast and prostate cancer:more similar than different EJ]- Nat Rev Cancer, 2010,10(3) :205-212.
  • 9Ma X, Holt D, Kundu N, et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE ( 2 )-mediated and inhibits breast cancer metastasisJ']. Oncoimmunology, 2013,2 (1) : e22647.
  • 10Dong Z, Bonfil RD, Chinni S, et al. Matrix metalloproteinase activity and osteoelasts in experimental prostate cancer bone metastasis tissueEJ]. AmJ Pathol,2005,166(4):l173-1186.

二级参考文献8

  • 1丁翔,严春寅,温端改,侯建全,浦金贤.COX-2、bcl-2和PCNA在前列腺癌中的表达及其意义[J].苏州大学学报（医学版）,2005,25(1):110-112. 被引量：10
  • 2Liu XH, Kirschenhaum A, Lu A, et al stimulates prostatic intraepithelial neoplasia Prostaglandin E ( 2 ) cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway [J]. Biochem Biophys Res Commun, 2002, 290( 1 ) : 249-255.
  • 3Shahedi K, Lindstrom S, Zheng SL, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk [ J ]. Int J Cancer, 2006, 119 (3) :668-672.
  • 4Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis[J]. Cancer Lett, 2003, 191(2): 125-135.
  • 5Narayanan BA, Reddy BS, Bosland MC, et al. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence[J]. Clin Cancer Res, 2007, 13(19) : 5965 -5973.
  • 6Smith MR, Manola J, Kaufman DS,et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy [J]. JClinOncol, 2006, 24(18) :2723-2728.
  • 7Pruthi RS, Derksen JE, Moore D,et al. Phase Ⅱ trial of celecoxib in prostate-speeific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy[ J]. Clin Cancer Res, 2006, 12(7 Pt 1 ) :2172-2177.
  • 8Caries J, Font A, Mellado B, et al. Weekly administration of docetaxel in combination with estramustine and eelecoxib in patients with advanced hormone-refractory prostate cancer: final results fromaphase Ⅱ study[J]. Br J Cancer, 2007, 97(9): 1206- 1210.

共引文献6

同被引文献15

  • 1Hess KR, terns in ad Varadhachary GR, Taylor SH, et al. Metastatic pat- Cancer, 2006, 106(7) : 1624-1633.
  • 2Weinfurt KP, Li Y, Castel LD, et al. The significance of skele- tal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oneol, 2005,16 (4) : 579- 584.
  • 3Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in trausgenic adenocarcinoma of the mouse prostate model. Cancer Res, 2004, 64(9) : 3334-3343.
  • 4Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non- steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet, 2002, 360(9339) : 1071-1073.
  • 5Xu S, Zhang Z, Ogawa O, et al. An EP4 antagonist ONO-AE3- 208 suppresses cell invasion, migration, and metastasis of pros- tate cancer. Cell Biochem Biophys, 2014 Apr 18.
  • 6Kundu N, Ma X, Kochel T, et al. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like proper- ties. Breast Cancer Res Treat, 2014, 143(1 ) : 19-31.
  • 7Ma X, Holt D, Kundu N, et al. A prostaglandin E (PGE) re- ceptor EP4 antagonist protects natural killer cells from PGE (2)- mediated immunosuppression and inhibits breast cancer metasta- sis. Oncoimmunology, 2013, 2(1 ) : e22647.
  • 8Ye L, Kynaston HG, Jiang WG. Bone metastasis in prostate cancer: Molecular and cellular mechanisms (Review). Int J Mol Med, 2007, 20(1) : 103-111.
  • 9Rentsch CA, Cecchini MG, Thalmann GN. Loss of inhibition over master pathways of bone mass regulation results in osteoscle- rotic bone metastases in prostate cancer. Swiss Med Wkly, 2009, 139(15-16) : 220-225.
  • 10Shamir D, Keila S, Weinreb M. A selective EP4 receptor anta- gonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitro. Bone, 2004. 34(1) : 157-162.

引证文献1

江苏医药
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部